BACKGROUND: True frequency of synchronous pelvic metastases with positive inguinal sentinel lymph node (SLN) biopsy is unknown. Role of pelvic dissection in the SLN era is unclear. METHODS: From 1994 to 2004, 1 surgeon routinely performed nonselective, complete inguinopelvic lymphadenectomy after positive inguinal SLN biopsy. All cases were identified from a prospectively maintained database. Clinicopathologic features associated with pelvic disease were assessed. RESULTS: A total of 40 patients with positive inguinal SLN underwent, without additional selection, 42 complete inguinopelvic lymphadenectomies. Median age was 46.5 years (range 25-79 years); 79% had lower extremity primaries. Median Breslow depth was 2.3 mm (range 1.0-10.0 mm), Clark's IV/V 98%, ulceration 26%. Frequency of synchronous pelvic disease upon completion lymphadenectomy was 5 of 42 (11.9%). Patients with and without pelvic disease were similar in age, sex, Breslow depth, Clark's level, ulceration, and mitoses. All 5 cases with pelvic metastases had extremity primaries (4 distal, 1 proximal). Of the 5, 3 (60%) had ≥3 total involved inguinal nodes, compared with only 1 (2.7%) of the 37 cases without pelvic disease (P=.003). Ratio of positive to total number inguinal nodes retrieved was >0.20 in 80% of cases with pelvic disease and 8.6% of cases without (P=.002). Upon lymphoscintigraphy review, secondary pelvic drainage was present in 80% of cases with pelvic disease compared with 56% of cases without pelvic disease, though the trend was statistically insignificant (P=.63). CONCLUSIONS: In this cohort of unselected, SLN-positive patients with complete inguinopelvic lymphadenectomy, frequency of synchronous pelvic disease was 11.9%. Patients with ≥3 total involved inguinal nodes or inguinal node ratio >0.20 appear more likely to harbor pelvic disease.
BACKGROUND: True frequency of synchronous pelvic metastases with positive inguinal sentinel lymph node (SLN) biopsy is unknown. Role of pelvic dissection in the SLN era is unclear. METHODS: From 1994 to 2004, 1 surgeon routinely performed nonselective, complete inguinopelvic lymphadenectomy after positive inguinal SLN biopsy. All cases were identified from a prospectively maintained database. Clinicopathologic features associated with pelvic disease were assessed. RESULTS: A total of 40 patients with positive inguinal SLN underwent, without additional selection, 42 complete inguinopelvic lymphadenectomies. Median age was 46.5 years (range 25-79 years); 79% had lower extremity primaries. Median Breslow depth was 2.3 mm (range 1.0-10.0 mm), Clark's IV/V 98%, ulceration 26%. Frequency of synchronous pelvic disease upon completion lymphadenectomy was 5 of 42 (11.9%). Patients with and without pelvic disease were similar in age, sex, Breslow depth, Clark's level, ulceration, and mitoses. All 5 cases with pelvic metastases had extremity primaries (4 distal, 1 proximal). Of the 5, 3 (60%) had ≥3 total involved inguinal nodes, compared with only 1 (2.7%) of the 37 cases without pelvic disease (P=.003). Ratio of positive to total number inguinal nodes retrieved was >0.20 in 80% of cases with pelvic disease and 8.6% of cases without (P=.002). Upon lymphoscintigraphy review, secondary pelvic drainage was present in 80% of cases with pelvic disease compared with 56% of cases without pelvic disease, though the trend was statistically insignificant (P=.63). CONCLUSIONS: In this cohort of unselected, SLN-positive patients with complete inguinopelvic lymphadenectomy, frequency of synchronous pelvic disease was 11.9%. Patients with ≥3 total involved inguinal nodes or inguinal node ratio >0.20 appear more likely to harbor pelvic disease.
Authors: Andrew J Page; Grant W Carlson; Keith A Delman; Douglas Murray; Andrea Hestley; Cynthia Cohen Journal: Am Surg Date: 2007-07 Impact factor: 0.688
Authors: Brian Badgwell; Yan Xing; Jeffrey E Gershenwald; Jeffrey E Lee; Paul F Mansfield; Merrick I Ross; Janice N Cormier Journal: Ann Surg Oncol Date: 2007-08-01 Impact factor: 5.344
Authors: Kelly M McMasters; Sandra L Wong; Michael J Edwards; Celia Chao; Merrick I Ross; R Dirk Noyes; Vicki Viar; Patricia B Cerrito; Douglas S Reintgen Journal: Ann Surg Oncol Date: 2002-03 Impact factor: 5.344
Authors: D R Murray; G W Carlson; R Greenlee; N Alazraki; C Fry-Spray; A Hestley; R Poole; M Blais; D S Timbert; J Vansant Journal: Am Surg Date: 2000-08 Impact factor: 0.688
Authors: Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Robert Elashoff; Richard Essner; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; Edwin C Glass; He-Jing Wang Journal: N Engl J Med Date: 2006-09-28 Impact factor: 91.245
Authors: Yan Xing; Brian D Badgwell; Merrick I Ross; Jeffrey E Gershenwald; Jeffrey E Lee; Paul F Mansfield; Anthony Lucci; Janice N Cormier Journal: Cancer Date: 2009-06-01 Impact factor: 6.860
Authors: D Verver; M F Madu; C M C Oude Ophuis; M Faut; J H W de Wilt; J J Bonenkamp; D J Grünhagen; A C J van Akkooi; C Verhoef; B L van Leeuwen Journal: Br J Surg Date: 2017-11-02 Impact factor: 6.939
Authors: Mikko Vuoristo; Timo Muhonen; Virve Koljonen; Susanna Juteau; Micaela Hernberg; Suvi Ilmonen; Tiina Jahkola Journal: BJS Open Date: 2021-11-09